Mastocytosis: Current concepts in diagnosis and treatment

Annals of Hematology

Volumn 81, Issue 12, 2002, Pages 677-690

  Escribano, L ^a   Akin, C ^b   Castells, M ^c   Orfao, A ^d   Metcalfe, D D ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

Diagnosis; Mast cell mediators; Mast cells; Mastocytosis; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALPHA2B INTERFERON; AMPHOTERICIN B; ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ESTROGEN; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; MORPHINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; POLYMYXIN B; QUININE; STEM CELL FACTOR; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D;

ANAPHYLAXIS; BLOOD CLOTTING DISORDER; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CARDIOTOXICITY; CAREGIVER; CELL COUNT; CELL INFILTRATION; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DRUG MECHANISM; GENERAL PRACTITIONER; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INFECTION; LIVER PARENCHYMA; LYMPH NODE; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT COUNSELING; PORTOCAVAL SHUNT; PRIORITY JOURNAL; PRURITUS; PUVA; REVIEW; SARCOMA; SKIN; SPLEEN; SPLENECTOMY; STOMACH DISEASE; TISSUE DISTRIBUTION; URTICARIA PIGMENTOSA;

HUMANS; INFLAMMATION MEDIATORS; MAST CELLS; MASTOCYTOSIS;

EID: 0036958893     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0575-z     Document Type: Review

References (176)

1. Riley JF, West GB (1953) The presence of histamine in tissue mast cells. J Physiol (Lond) 120:528-537
2. Schwartz LB, Irani AM, Roller K, Castells MC, Schechter NM (1987) Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 138:2611-2615
3. Falus A, Meretey K (1992) Histamine: an early messenger in inflammatory and immune reactions. Immunol Today 13:154-156
4. Inoue I, Yanai K, Kitamura D, Taniuchi I, Kobayashi T, Niimura K, Watanabe T, Watanabe T (1996) Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A 93:13316-13320
5. Schwartz LB, Lewis RA, Austen KF (1981) Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem 256:11939-11943
6. Caughey GH, Raymond WW, Blount JL, Hau LWT, Pallaoro M, Wolters PJ, Verghese GM (2000) Characterization of human gamma-tryptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families. J Immunol 164:6566-6575
7. Schwartz LB (2001) Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 25:553-562
8. Caughey GH, Zerweck EH, Vanderslice P (1991) Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem 266:12956-12963
9. Caughey GH, Raymond WW, Wolters PJ (2000) Angiotensin II generation by mast cell α- and β-chymases. Biochim Biophys Acta Protein Struct Mol Enzymol 1480:245-257
10. Goldstein SM, Kaempfer CE, Kealey JT, Wintroub BU (1989) Human mast cell carboxypeptidase. Purification and characterization. J Clin Invest 83:1630-1636
11. Nugent MA, Iozzo RV (2000) Fibroblast growth factor-2. Int J Biochem Cell Biol 32:115-120
12. Holgate ST, Burns GB, Robinson C, Church MK (1984) Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J Immunol 133:2138-2144
13. Lewis RA, Austen KF (1984) The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest 73:889-897
14. Benyon RC, Robinson C, Church MK (1989) Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br J Pharmacol 97:898-904
15. Morrow JD, Minton TA, Awad JA, Roberts LJ (1994) Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans following the application of sorbic acid. Arch Dermatol 130:1408-1412
16. Joris I, Majno G, Corey EJ, Lewis RA (1987) The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am J Pathol 126:19-24
17. Penrose JF, Gagnon L, Goppelt-Struebe M, Myers P, Lam BK, Jack RM, Austen KF, Soberman RJ (1992) Purification of human leukotriene C4 synthase. Proc Natl Acad Sci U S A 89:11603-11606
18. Arm JP, Lee TH (1993) Sulphidopeptide leukotrienes in asthma. Clin Sci (Lond) 84:501-510
19. Holgate ST, Bradding P, Sampson AP (1996) Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 98:1-13
20. Barnes N, Piper PJ, Costello J (1987) The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol 79:816-821
21. Hui KP, Barnes NC (1991) Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 337:1062-1063
22. Barnes PJ, Chung KF, Page CP (1988) Platelet-activating factor as a mediator of allergic disease. J Allergy Clin Immunol 81:919-934
23. Macpherson JL, Kemp A, Rogers M, Mallet AI, Toia RF, Spur B, Earl JW, Chesterman CN, Krilis SA (1989) Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol 77:391-396
24. Gordon JR, Galli SJ (1990) Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature 346:274-276
25. Malaviya R, Ikeda T, Ross E, Abraham SN (1996) Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 381:77-80
26. Gordon JR (2000) TGFβ1 and TNFα secreted by mast cells stimulated via the FcERI activate fibroblasts for high-level production of monocyte chemoattractant protein-1 (MCP-I). Cell Immunol 201:42-49
27. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194:809-821
28. Kitamura Y, Tsujimura T, Jippo T, Kasugai T (1994) Regulation of mast cell development by c-kit receptor and its ligand. Acta Histochem Cytochem 27:17-22
29. Galli SJ, Tsai M, Wershil BK, Tam S-Y, Costa JJ (1995) Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int Arch Allergy Immunol 107:51-53
30. De Paulis A, Minopoli G, Arbustini E, De Crescenzo G, Dal Piaz F, Pucci P, Russo T, Marone G (1999) Stem cell factor is localized in, released from, and cleaved by human mast cells. J Immunol 163:2799-2808
31. Longley BJ, Jr, Morganroth GS, Tyrrell L, Ding TG, Anderson DM, Williams DE, Halaban R (1993) Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 328:1302-1307
32. Castells MC, Friend DS, Bunnell CA, Hu XZ, Kraus M, Osteen RT, Austen KF (1996) The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol 98:831-840
33. Akin C, Schwartz LB, Kitoh T, Obayashi H, Worobec AS, Scott LM, Metcalfe DD (2000) Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 96:1267-1273
34. Bradding P, Feather IH, Howarth PH, Mueller R, Roberts JA, Britten K, Bews JPA, Hunt TC, Okayama Y, Heusser CH, Bullock GR, Church MK, Holgate ST (1992) Interleukin 4 is localized to and released by human mast cells. J Exp Med 176:1381-1386
35. Pawankar R, Okuda M, Yssel H, Okumura K, Ra CS (1997) Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the FcERI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 99:1492-1499
36. 4 synthase pathway in mouse mast cells. J Biol Chem 270:22653-22656
37. 4 synthase expression by interleukin 4. J Exp Med 193:123-133
38. Mellor EA, Maekawa A, Austen KF, Boyce JA (2001) Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci U S A 98:7964-7969
39. Jaffe JS, Glaum MC, Raible DG, Post TJ, Dimitry E, Govindarao D, Wang YH, Schulman ES (1995) Human lung mast cell IL-5 gene and protein expression: Temporal analysis of upregulation following IgE-mediated activation. Am J Respir Cell Mol Biol 13:665-675
40. Bressler RB, Lesko J, Jones ML, Wasserman M, Dickason RR, Huston MM, Cook SW, Huston DP (1997) Production of IL-5 and granulocyte-macrophage colony -stimulating factor by naive human mast cells activated by high-affinity IgE receptor ligation. J Allergy Clin Immunol 99:508-514
41. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST (1994) Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 10:471-480
42. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP (1997) Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 66:54-62
43. Kobayashi H, Okayama Y, Ishizuka T, Pawankar R, Ra C, Mori M (1998) Production of IL- 13 by human lung mast cells in response to FcE receptor cross-linkage. Clin Exp Allergy 28:1219-1227
44. Valent P, Horny H-P, Escribano L, Longley J, Li CL, Schwartz LB, Marone G, Núñez R, Akin C, Sotlar K, Sperr W, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert AK, Metcalfe D, Vardiman JW, Bennet JM (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25:603-625
45. Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, Chott A, Lechner K, Lennert K, Valent P (1998) Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 22:1132-1140
46. Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD (2002) An immunohistochemical study of the bone marrow lesions of systemic mastocytosis - expression of stem cell factor by lesional mast cells. Am J Clin Pathol 118:242-247
47. Escribano L, Orfao A, Díaz Agustín B, Villarrubia J, Cerveró C, López A, García Marcos A, Bellas C, Fernández Cañadas S, Cuevas M, Sanchez A, Velasco JL, Navarro JL, San Miguel JF (1997) Indolent systemic mast cell disease in adults. immunophenotypic characterization and its diagnostic implications. Blood 91:2731-2736
48. Escribano L, Díaz Agustín B, Bellas C, Navalón R, Núñez R, Sperr W, Schernthaner G, Valent P, Orfao A (2001) Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 25:563-570
49. Nuñez R, Escribano L, Schernthaner G, Prados A, Rodriguez-Gonzalez R, Diaz-Agustin B, Lopez A, Hauswirth A, Valent P, Almeida J, Bravo P, Orfao A (2002) Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. Br J Haematol, in press
50. Díaz Agustín B, Escribano L, Bravo P, Herrero S, Nuñez R, Navalón R, Torrelo A, Cantalapiedra A, Del Castillo L, Villarrubia J, Navarro JL, San Miguel JF, Orfao A (1999) The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. Br J Haematol 106:400-405
51. Granerus G, Roupe G (1982) Increased urinary methylimida-zoleacetic acid (MelmAA) as an indicator of systemic mastocytosis. Agents Actions 12:29-31
52. Granerus G, Olafsson JH, Roupe G (1983) Studies on histamine metabolism in mastocytosis. J Invest Dermatol 80:410-416
53. Keyzer JJ, de Monchy JG, Van Doormaal JJ, Voorst Vader PC (1983) Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 309:1603-1605
54. Akin C, Metcalfe DD (2002) Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol 127:133-136
55. Lerno G, Slaats G, Coenen E, Herregods L, Rolly G (1990) Anaesthetic management of systemic mastocytosis. Br J Anaesth 65:254-257
56. Goins VA (1991) Mastocytosis. Perioperative considerations. AORN J 54:1227-1238
57. Metcalfe DD (1991) The treatment of mastocytosis: an overview. J Invest Dermatol 96:55S-56S
58. Longley J, Duffy TP, Kohn S (1995) The mast cell and mast cell disease. J Am Acad Dermatol 32:545-561
59. Stellato C, De Crescenzo G, Patella V, Mastronardi P, Mazzarella B, Marone G (1996) Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release. J Allergy Clin Immunol 97:838-850
60. Elberink JNGO, De Monchy JGR, Kors JW, Van Doormaal JJ, Dubois AEJ (1997) Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 99:153-154
61. Fricker M, Helbling A, Schwartz L, Müller U (1997) Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 100: 11-15
62. Peachell PT, Morcos SK (1998) Effect of radiographic contrast media on histamine release from human mast cells and basophils. Br J Radiol 71:24-30
63. Alto WA, Clarcq L (1999) Cutaneous and systemic manifestations of mastocytosis. Am Fam Physician 59:3047-3060
64. Teuber SS, Vogt PJ (1999) An unproven technique with potentially fatal outcome: provocation/neutralization in a patient with systemic mastocytosis. Ann Allergy Asthma Immunol 82:61-65
65. Stellato C, De Paulis A, Cirillo R, Mastronardi P, Mazzarella B, Marone G (1991) Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 74:1078-1086
66. Marone G, Stellato C (1992) Activation of human mast cells and basophils by general anaesthetic drugs. Monogr Allergy 30:54-73
67. Stellato C, Marone G (1995) Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Chem Immunol 62:108-131
68. Coleman MA, Liberthson RR, Crone RK, Levine FH (1980) General anesthesia in a child with urticaria pigmentosa. Anesth Analg 59:704-706
69. Scott HW, Jr, Parris WC, Sandidge PC, Oates JA, Roberts LJ (1983) Hazards in operative management of patients with systemic mastocytosis. Ann Surg 197:507-514
70. Desborough JP, Taylor I, Hattersley A, Garden A, Wolff A, Bloom SR, Morgan M (1990) Massive histamine release in a patient with systemic mastocytosis. Br J Anaesth 65:833-836
71. Greenblatt EP, Chen L (1990) Urticaria pigmentosa: an anesthetic challenge. J Clin Anesth 2:108-115
72. Brodier C, Guyot E, Palot M, David P, Rendoing J (1993) Anesthesia of a child with a cutaneous mastocytosis. Cah Anesthesiol 41:77-79
73. Ojeda A, Crespo A, Crespo V, Sánchez F, Sanz A, Vera A (1996) Telangiectasia maculosa eruptiva persistente con afectación sistémica y evolución postoperatoria fatal. Actas Dermosifiliogr 87:539-542
74. Vaughan STA, Jones GN (1998) Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia 53:804-807
75. Tirel O, Chaumont A, Ecoffey C (2001) Circulatory arrest in the course of anesthesia for a child with mastocytosis. Ann Fr Anesth Reanim 20:874-875
76. James PD, Krafchik BR, Johnston AE (1987) Cutaneous mastocytosis in children: anaesthetic considerations. Can J Anaesth 34:522-524
77. Delalande JP, Rea D, Fenoll B (1992) Absence of mast cell degranulation during general anesthesia in a child with mastocytosis. Ann Fr Anesth Reamm 11:393-394
78. Yaniv R, Segal E, Perel A (1992) Anesthetic considerations in mast-cell proliferative disease (urticaria pigmentosa and mastocytosis). Harefuah 122:780-784
79. Koitabashi T, Takino Y (1995) Anesthetic management of a patient with urticaria pigmentosa. Masui 44:279-281
80. Borgeat A, Ruetsch YA (1998) Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique. Anesth Analg 86:442-444
81. Auvray L, Letourneau B, Freysz M (2001) Mastocytosis: general anesthesia with remifentanil and sevoflurane. Ann Fr Anesth Reanim 20:635-638
82. Worobec AS (2000) Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 14:659-687
83. Fisher MM, Baldo BA (1998) Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth 80:26-29
84. Lorenzi P, Filoni M, Manetta G, Bonechi ML, Salvati G, Tanini A (1999) Reazione anafilattica at tiopentale. Un caso documentato dalla positivita delta triptasi sierica e del RAST. Minerva Anestesiol 65:659-663
85. Austen KF (1992) Systemic mastocytosis. N Engl J Med 326:639-640
86. Friedman BS, Santiago ML, Berkebile C, Metcalfe DD (1993) Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis, J Allergy Clin Immunol 92:520-526
87. Apter AJ, Rothe MJ (1997) Referred for management of mastocytosis. Ann Allergy Asthma Immunol 79:21-26
88. Golkar L, Bernhard JD (1997) Mastocytosis. Lancet 349:1379-1385
89. Kurosawa M, Amano H, Kanbe N, Akimoto S, Takeuchi Y, Yamashita T, Hashimoto T, Kurimoto F, Miyachi Y (1997) Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis. J Allergy Clin Immunol 100:S25-S32
90. Worobec AS, Metcalfe DD (2002) Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 127:153-155
91. Poterack CD, Sheth KJ, Henry DP, Eisenberg C (1989) Shock in an infant with bullous mastocytosis. Pediatr Dermatol 6:122-125
92. Walton J (1989) Mastocytosis/vasodilatory shock in a 25-year-old woman. J Emerg Nurs 15:356-357
93. Horan RF, Austen KF (1991) Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 96:5S-13S
94. Gonera RK, Oranje WA, Wolffenbuttel BH (1997) Shock of unknown origin - think of mastocytosis! Neth J Med 50:165-169
95. Worobec AS, Metcalfe DD (1996) In: Fancy AS, Lichtenstein LB (eds) Current therapy in allergy, immunology, and rheumatology. Mosby-Year Book, St. Louis
96. Simons FER, Gu XC, Silver NA, Simons KJ (2002) EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy Clin Immunol 109:171-175
97. Metcalfe DD (1991) Clinical advances in mastocytosis: an interdisciplinary roundtable discussion. J Invest Dermatol 96 [Suppl]:1S-65S
98. Bianchine PJ, Metcalfe DD (1997) Systemic mastocytosis. In: Kaplan AP (ed) Allergy. WB Saunders, Philadelphia
99. Marone G, Spadaro G, Granata F, Triggiani M (2001) Treatment of mastocytosis: pharmacologic basis and current concepts. Leuk Res 25:583-594
100. Zhang MQ (1997) Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 4:171-184
101. Fenske NA, Lober CW, Pautler SE (1985) Congenital bullous urticaria pigmentosa. Treatment with concomitant use of H1-and H2-receptor antagonists. Arch Dermatol 121:115-118
102. Frieri M, Alling DW, Metcalfe DD (1985) Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am J Med 78:9-14
103. 2 receptor antagonists. Dermatologica 184:149-152
104. Hirschowitz BI, Groarke JF (1979) Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann Intern Med 90:769-771
105. Johnson GJ, Silvis SE, Roitman B, Blumenthal M, Gilbert HS (1980) Long-term treatment of systemic mastocytosis with histamine H2 receptor antagonists. Am J Gastroenterol 74:485-489
106. Berg MJ, Bernhard H, Schentag JJ (1981) Cimetidine in systemic mastocytosis. Drug Intell Clin Pharm 15:180-183
107. Collen MJ, Howard JM, McArthur KE, Raufman JP, Cornelius MJ, Ciarleglio CA, Gardner JD, Jensen RT (1984) Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 100:52-58
108. Debeuckelaere S, Schoors DF, Devis G (1991) Systemic mast cell disease: a review of the literature with special focus on the gastrointestinal manifestations. Acta Clin Belg 46:226-232
109. 3 receptor antagonists: Synthesis and evaluation of formamidine and S-methylisothiourea derivatives. Chem Pharm Bull (Tokyo) 45:305-311
110. 3-receptors and pharmacology of betahistine. Acta Otolaryngol (Stockh) 117:43-46
111. 3 receptor antagonists. J Med Chem 43;2362-2370
112. 3 receptor-mediated inhibition of intestinal acetyl-choline release: pharmacological characterization of signal transduction pathways. Naunyn Schmiedebergs Arch Pharmacol 363:193-202
113. Dolovich J, Punthakee ND, MacMillan AB, Osbaldeston GJ (1974) Systemic mastocytosis: control of lifelong diarrhea by ingested disodium cromoglycate. Can Med Assoc J 111:684-685
114. Soter NA, Austen KF, Wasserman SI (1979) Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 301:465-469
115. Horan RF, Sheffer AL, Austen KF (1990) Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 85:852-855
116. Haustein UF, Bedri M (1997) Bullous mastocytosis in a child. Hautarzt 48:127-129
117. Welch EA, Alper JC, Bogaars H, Farrell DS (1983) Treatment of bullous mastocytosis with disodium cromoglycate. J Am Acad Dermatol 9:349-353
118. Leaf FA, Jaecks EP, Rodriguez DR (1996) Bullous urticaria pigmentosa. Cutis 58:358-360
119. Alexander RR (1985) Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone. Acta Haematol 74:108-110
120. Miner PB, Jr (1991) The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. J Invest Dermatol 96:40S-44S
121. 2) antagonist and cyclooxygenase inhibition. Clin Invest Med 10:1-4
122. Butterfield JH, Kao PC, Klee GG, Yocum MW (1995) Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc 70:481-487
123. Mackey S, Pride HB, Tyler WB (1996) Diffuse cutaneous mastocytosis - treatment with oral psoralen plus UV-A. Arch Dermatol 132:1429-1430
124. Godt O, Proksch E, Streit V, Christophers E (1997) Short-and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 195:35-39
125. Christophers E, Honigsmann H, Wolff K, Langner A (1978) PUVA-treatment of urticaria pigmentosa. Br J Dermatol 98:701-702
126. Czarnetzki BM, Rosenbach T, Kolde G, Frosch PJ (1985) Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes. Arch Dermatol Res 277:105-113
127. Kolde G, Frosch PJ, Czarnetzki BM (1984) Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural, and biochemical investigations. J Invest Dermatol 83:175-178
128. Smith ML, Orton PW, Chu H, Weston WL (1990) Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. Pediatr Dermatol 7:251-255
129. Stege H, Schopf E, Ruzicka T, Krutmann J (1996) High-dose UVA1 for urticaria pigmentosa. Lancet 347:64
130. van Furth AM, van de Rhee HJ, van Zwieten PH, Nauta-Billig S (1993) Congenitate bulleuze urticaria pigmentosa. Tijdschr Kindergeneeskd 61:58-62
131. Vella-Briffa D, Eady RA, James MP, Gatti S, Bleehen SS (1983) Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. Br J Dermatol 109:67-75
132. Kettelhut BV, Metcalfe DD (1991) Pediatric mastocytosis. J Invest Dermatol 96:15S-18S
133. Borroni G, Vignati G, Zaccone C, Gorani A, Brazzelli V, Rabbiosi G (1994) Photofibrosis: a further histopathological change induced by PUVA therapy via the mast cell in guttate psoriasis. Preliminary report. Acta Derm Venereol (Stockh) 74 [Suppl 186]:159-161
134. Stern RS, Nichols KT, Vakeva LH (1997) Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 336:1041-1045
135. Wallenfang K, Stadler R (2001) Association between UVA1 and PUVA bath therapy and development of malignant melanoma. Hautarzt 52:705-707
136. Ellis DL (1996) Treatment of telangiectasia macularis eruptiva perstans with the 585-nm flashlamp-pumped dye laser. Dermatol Surg 22:33-37
137. Sarkany RP, Monk BE, Handfield-Jones SE (1998) Telangiectasia macularis eruptiva perstans: a case report and review of the literature. Clin Exp Dermatol 23:38-39
138. Grundfest S, Cooperman AM, Ferguson R, Benjamin S (1980) Portal hypertension associated with systemic mastocytosis and splenomegaly. Gastroenterology 78:370-373
139. Smith GB, Gusberg RJ, Jordan RH, Kim B (1987) Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis. Anaesthesia 42:861-867
140. Friedman B, Darling G, Norton J, Hamby L, Metcalfe D (1990) Splenectomy in the management of systemic mast cell disease. Surgery 107:94-100
141. Abraham EK, Augustine J, Amma S, Nair K (1992) Malignant systemic mastocytosis. Indian J Cancer 29:192-197
142. Delacretaz F, Stalder M, Meuge-Moraw C, Schmidt PM, Joris F, Kurt AM, De Werra P (1997) Systemic mastocytosis following a malignant ovarian germ cell tumour. Histopathology 30:582-584
143. Klum-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, Willemze R (1992) Response to interferon ALFA-2b in a patient with systemic mastocytosis. N Engl J Med 326:619-623
144. Schernthaner GH, Spanblöchl E, Sperr WR, Sillaber C, Semper H, Jurecka W, Hagen M, Wolff K, Chott A, Lechner K, Valent P (2000) Effects of interferon-α2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann Hematol 79:660-666
145. Sewell KL (1993) Immunotherapy and other novel therapies, including biologic response modifiers, apheresis, and dietary modifications. Curr Opin Rheumatol 5:293-298
146. Essner C, Thiefin G, Diebold MD, Pignon B, Caulet T, Zeitoun P (1995) Ascite lymphocytaire revelatrice d'une mastocytose systemique. Gastroenterol Clin Biol 19:948-951
147. Fain O, Sitbon M, Sibony M, Frilay Y, Mathieu E, Lejeune F, Thomas M (1995) Efficacite de l'interferon alpha dans un cas de mastocytose systemique. Ann Med Interne (Paris) 146:205-206
148. Escribano L, Orfao A, Villarrubia J, Martín F, Madruga JI, Cuevas M, Velasco JL, Rios A, San Miguel JF (1997) Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 30:98-102
149. Hübner C, Wedding U, Strater J, Limberg B, Stremmel W (1997) Clinical stable systemic mastocytosis with interferon alpha-2b therapy. J Intern Med 241:529-533
150. las-Nieves M, Poveda F, Queipo-de-Llano MP, Gonzalez-Hermoso C (1997) Mastocitosis sistemica: presentacion de un caso con evolucion a mielofibrosis y nula respuesta a interferon alpha Ilb. Sangre (Barc) 42:430-431
151. Brunel V, Tadrist Z, Cailleres S, Allegre T, Blanc AP (1998) Interferon alpha and pamidronate: a useful combination for osteoporosis in systemic mastocytosis. Presse Med 27:64
152. Butterfield JH (1998) Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 138:489-495
153. Chosidow O, Bécherel PA, Piette JC, Arock M, Debré P, Francés C (1998) Tripe palms associated with systemic mastocytosis: the role of transforming growth factor-α and efficacy of interferon-alfa. Br J Dermatol 138:698-703
154. Giraldo-Castellano P, Garcia-Erce JA, Alvarez-Alegret R, Arroyo-Rubio A, Mayayo-Artal P, Vicente-Camara P, Rubio-Felix D, Giralt-Raichs M (1998) Interferon-alpha y mastocitosis sistemica. Análisis de la eficacia terapéutica en seis casos. Rev Clin Esp 198:345-350
155. Kennedy RJ, Scoffield JL, Garstin WIH (1999) An unusual presentation of systemic mastocytosis. J Clin Pathol 52:301-302
156. Wong KF, Chan JKC, Chan JCW, Kwong YL, Ma SK, Chow TC (1991) Concurrent acute myeloid leukemia and systemic mastocytosis. Am J Hematol 38:243-244
157. Worobec AS, Semere T, Nagata H, Metcalfe DD (1998) Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 83:2120-2129
158. Wimazal F, Sperr WR, Horny HP, Carroll V, Binder BR, Fonatsch C, Walchshofer S, Födinger M, Schwarzinger I, Samorapoompichit P, Chott A, Dvorak AM, Lechner K, Valent P (1999) Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol 61:66-77
159. Travis WD, Li C-Y, Bergstralh EJ (1989) Solid and hematologic malignancies in 60 patients with systemic mast cell disease. Arch Pathol Lab Med 113:365-368
160. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR (1991) Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 91:612-624
161. Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, Vernant JP, Tulliez M (1997) A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 96:374-376
162. Dalton R, Chan L, Batten E, Eridani S (1986) Mast cell leukaemia: evidence for bone marrow origin of the pathological clone. Br J Haematol 64:397-406
163. Travis WD, Li CY, Hoagl HC, Travis LB, Banks PM (1986) Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 61:957-966
164. Torrey E, Simpson K, Wilbur S, Munoz P, Skikne B (1990) Malignant mastocytosis with circulating mast cells. Am J Hematol 34:283-286
165. Sugita K, Kaneko T, Sekine Y, Taguchi N, Miyauchi J (1996) Mast cell leukemia evolved from RAEB-T (5q-syndrome) in a 12 year-old girl (in Japanese). Rinsho Ketsueki 37:430-436
166. Le Cam MT, Wolkenstein P, Cosnes A, Bocquet H, Gaulard P, Tulliez M, Cordonnier C, Roujeau JC, Bagot M, Revuz J (1997) Leucemie aigue a mastoblastes revelee par des bouffees vasomotrices. Ann Dermatol Venereol 124:621-622
167. Kurosawa M, Amano H, Kanbe N, Igarashi Y, Nagata H, Yamashita T, Kurimoto F, Miyachi Y (1999) Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis. J Allergy Clin Immunol 103:S412-S420
168. Tefferi A, Li CY, Butterfield JH, Hoagland HC (2001) Treatment of systemic mast-cell disease with cladribine. N Engl J Med 344:307-309
169. Escribano L, Pérez de Oteyza J, Núñez R, Orfao A (2002) Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma. Leuk Res 26:1043-1046
170. Ma YS, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-1744
171. Akin C, Longley BJ, Brockow K, Metcalfe D (2000) Effects of tirosine-kinase inhibitor STI571 on mutated KIT and neoplastic mast cells. Blood 99:3231a
172. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880
173. Ronnov-Jessen D, Lovgreen NP, Horn T (1991) Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 8:413-415
174. Fodinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H, Valent P, Mannhalter C (1994) Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 84:2954-2959
175. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C (1998) Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 57:24-28
176. Sperr WR, Horny HP, Lechner K, Valent P (2000) Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 37:473-486